替罗非班在急性冠状动脉综合征患者介入术中应用价值

目的研究冠状动脉内注射盐酸替罗非班在急性冠状动脉综合征（ACS）介入治疗中的应用疗效和安全性。方法将100例急诊或择期行经皮冠状动脉介入治疗（PCI）的ACS患者分为盐酸替罗非班组（50例）和对照组（50例）。对照组使用阿司匹林、氯吡格雷和肝素。盐酸替罗非班组在以上药物治疗的基础上,给予欣维宁（国产替罗非班）。观察两组患者用药后对冠状动脉再灌注的分级（TIMI 0～3级）及术后主要不良心血管事件、血小板减少、其他出血并发症的发生率。结果 PCI术后TIMI 3级血流获得率盐酸替罗非班组明显高于对照组（P〈0.05）。盐酸替罗非班组术后1个月内主要不良心脏事件发生率较对照组显著降低（P〈0.05）。围术期出血并发症较对照组稍高,差异无统计学意义（P〉0.05）。两组术后血小板计数差异无统计学意义（P〉0.05）。结论在ACS介入治疗中冠脉内注射盐酸替罗非班可以明显改善PCI术后的冠脉血流和心肌灌注,降低不良心脏事件发生率,疗效好且安全。

Application value of Tirofiban in intervention therapy for acute coronary syndrome

Objective To investigate the clinical effects and artery during intervention therapy of acute coronary syndrome satiety of Tiroiiban Hydrochloride Injection in coronary （ACS）. Methods 100 patients with ACS received emergent or selective percutaneous coronary intervention （PCI） were divided into Tirofiban Hydrochloride group （50 cases） and control group （50 cases）. The control group was treated by Aspirin, Clopidogrel and Heparin, while Tirofiban Hydrochloride group was treated by Xinweining （Tirofiban made in China） on the basis of above drugs. The grading of coronary reperfusion （TIMI 0-3 grade） and incidence of postoperative major adverse cardiovascular events, thrombocytopenia and other bleeding complications were observed. Results After PCI, the pick-up rate of TIMI 3 grade blood flow in Tirofiban Hydroehloride group was significantly larger than that of control group （P 〈 0.05）. In one month after PCI, the incidence of major adverse cardiovascular events in Tirofiban Hydrochloride group was significantly smaller than that of control group （P 〈 0.05）. The incidence of bleeding complication during perioperative in Tirofiban Hydroehloride group was slightly larger than that of control group （P 〉 0.05）. There was no statistic difference of platelet count after operation between the two groups （P 〉 0.05）. Conclusion For ACS, Tirofiban Hydrochloride Injection in coronary artery during intervention therapy can significantly improve the coronary blood flow and myocardial perfusion after PCI, decrease the incidence of adverse cardiovascular events, has good efficacy and safety.